Moderna Company Insiders
MRNA Stock | USD 43.06 0.33 0.76% |
Moderna's insiders are aggressively selling. The analysis of the overall insider sentiment regarding Moderna suggests that vertually all insiders are panicking. Moderna employs about 5.6 K people. The company is managed by 24 executives with a total tenure of roughly 13067 years, averaging almost 544.0 years of service per executive, having 233.33 employees per reported executive.
Moderna's Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
2024-10-07 | James M Mock | Disposed 715 @ 60.12 | View | ||
2024-09-03 | Shannon Thyme Klinger | Disposed 114 @ 76.99 | View | ||
2024-08-29 | Stephen Hoge | Disposed 300 @ 78.03 | View | ||
2024-08-28 | James M Mock | Disposed 1321 @ 79.39 | View | ||
2024-08-12 | Stephen Hoge | Disposed 254 @ 84.1 | View | ||
2024-07-31 | Noubar Afeyan | Disposed 15000 @ 119.96 | View | ||
2024-07-24 | Noubar Afeyan | Disposed 15000 @ 117.8 | View | ||
2024-07-17 | Noubar Afeyan | Disposed 15000 @ 122.84 | View | ||
2024-07-15 | Stephen Hoge | Disposed 15000 @ 121.12 | View | ||
2024-07-10 | Noubar Afeyan | Disposed 15000 @ 117.08 | View | ||
2024-07-08 | James M Mock | Disposed 689 @ 118.24 | View | ||
2024-06-26 | Noubar Afeyan | Disposed 15000 @ 127.22 | View | ||
2024-06-17 | Stephen Hoge | Disposed 15000 @ 138.16 | View | ||
2024-06-11 | Noubar Afeyan | Disposed 202832 @ 148.34 | View | ||
2024-06-10 | Shannon Thyme Klinger | Disposed 5178 @ 148.09 | View | ||
2024-06-05 | Noubar Afeyan | Disposed 15000 @ 151.25 | View | ||
2024-05-29 | Noubar Afeyan | Disposed 20000 @ 145.08 | View |
Monitoring Moderna's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Moderna |
Moderna's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Moderna's future performance. Based on our forecasts, it is anticipated that Moderna will maintain a workforce of about 5600 employees by December 2024.Moderna's latest congressional trading
Congressional trading in companies like Moderna, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Moderna by those in governmental positions are based on the same information available to the general public.
Moderna Management Team Effectiveness
The company has return on total asset (ROA) of (0.0955) % which means that it has lost $0.0955 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1752) %, meaning that it created substantial loss on money invested by shareholders. Moderna's management efficiency ratios could be used to measure how well Moderna manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.24. The current year's Return On Capital Employed is expected to grow to -0.26. At present, Moderna's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 23.1 B, whereas Other Current Assets are forecasted to decline to about 462.8 M.The current year's Net Income Applicable To Common Shares is expected to grow to about 10.1 B, whereas Common Stock Shares Outstanding is forecasted to decline to about 346.5 M.
Moderna Workforce Comparison
Moderna is considered to be number one stock in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 16,716. Moderna totals roughly 5,600 in number of employees claiming about 34% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.44) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.04) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.04. Moderna Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Moderna insiders, such as employees or executives, is commonly permitted as long as it does not rely on Moderna's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Moderna insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-12-01 | 1.5 | 6 | 4 | 17,500 | 2,968 |
2024-09-01 | 0.375 | 15 | 40 | 21,214 | 90,761 |
2024-06-01 | 0.2131 | 26 | 122 | 111,919 | 478,912 |
2024-03-01 | 0.5789 | 22 | 38 | 518,103 | 144,124 |
2023-12-01 | 0.2414 | 7 | 29 | 11,906 | 112,710 |
2023-09-01 | 0.1077 | 7 | 65 | 23,990 | 224,045 |
2023-06-01 | 0.2133 | 32 | 150 | 566,151 | 2,115,307 |
2023-03-01 | 0.157 | 27 | 172 | 779,321 | 2,186,271 |
2022-12-01 | 0.1467 | 33 | 225 | 655,834 | 2,364,736 |
2022-09-01 | 0.1164 | 27 | 232 | 509,562 | 2,451,426 |
2022-06-01 | 0.2133 | 48 | 225 | 410,136 | 1,801,403 |
2022-03-01 | 0.2407 | 39 | 162 | 465,934 | 918,687 |
2021-12-01 | 0.289 | 63 | 218 | 401,667 | 1,389,250 |
2021-09-01 | 0.2478 | 56 | 226 | 365,000 | 1,572,003 |
2021-06-01 | 0.3213 | 107 | 333 | 616,404 | 1,461,570 |
2021-03-01 | 0.1615 | 73 | 452 | 749,131 | 11,566,604 |
2020-12-01 | 0.1495 | 45 | 301 | 524,296 | 1,575,981 |
2020-09-01 | 0.203 | 67 | 330 | 1,268,963 | 23,944,558 |
2020-06-01 | 0.1613 | 45 | 279 | 2,430,487 | 18,379,608 |
2020-03-01 | 0.1491 | 17 | 114 | 1,734,649 | 1,095,566 |
2019-12-01 | 0.2353 | 8 | 34 | 1,217,171 | 11,306,769 |
2019-09-01 | 0.3333 | 1 | 3 | 100,000 | 205,000 |
2018-12-01 | 0.2716 | 22 | 81 | 61,587,803 | 48,565,415 |
2018-06-01 | 5.5 | 11 | 2 | 1,243,077 | 0.00 |
2014-03-01 | 1.0 | 3 | 3 | 1,493,606 | 108,041 |
2011-09-01 | 7.0 | 7 | 1 | 982,500 | 40,200 |
2011-03-01 | 0.038 | 3 | 79 | 126,253 | 404,005 |
2010-09-01 | 0.5 | 3 | 6 | 35,938 | 237,850 |
2009-03-01 | 4.0 | 4 | 1 | 1,091,275 | 800,000 |
2008-09-01 | 1.0 | 5 | 5 | 10,000 | 1,190 |
Moderna Notable Stakeholders
A Moderna stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Moderna often face trade-offs trying to please all of them. Moderna's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Moderna's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Shannon Klinger | Chief Secretary | Profile | |
Brad Miller | Chief Officer | Profile | |
Melanie MBA | Chief Officer | Profile | |
James Mock | Chief Officer | Profile | |
Stephane Bancel | CEO Director | Profile | |
John Reynders | Chief Officer | Profile | |
Ruchi Jain | Principal Scientist | Profile | |
Dave Johnson | Chief Officer | Profile | |
Lavina CFA | Senior Relations | Profile | |
Melissa Moore | Chief Board | Profile | |
Noubar Afeyan | Independent CoFounder | Profile | |
Stephen MD | President | Profile | |
Shannon JD | Chief Secretary | Profile | |
Allison MD | Senior Development | Profile | |
Colleen Hussey | Senior Communications | Profile | |
Patrick Bergstedt | Senior Vaccines | Profile | |
Tracey Franklin | Chief Officer | Profile | |
Michelle Hall | Principal Chemistry | Profile | |
Phil White | Vice Management | Profile | |
Lori Panther | Infectious Development | Profile | |
Jerh Collins | Chief Officer | Profile | |
Juan Andres | Pres Expansion | Profile | |
Charbel MPH | Senior Science | Profile | |
MD FAAP | Senior Development | Profile |
About Moderna Management Performance
The success or failure of an entity such as Moderna often depends on how effective the management is. Moderna management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Moderna management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Moderna management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.26) | (0.24) | |
Return On Capital Employed | (0.28) | (0.26) | |
Return On Assets | (0.26) | (0.24) | |
Return On Equity | (0.34) | (0.32) |
Please note, the presentation of Moderna's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Moderna's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Moderna's management manipulating its earnings.
Moderna Workforce Analysis
Traditionally, organizations such as Moderna use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Moderna within its industry.Moderna Manpower Efficiency
Return on Moderna Manpower
Revenue Per Employee | 1.2M | |
Revenue Per Executive | 285.3M | |
Net Loss Per Employee | 841.8K | |
Net Loss Per Executive | 196.4M | |
Working Capital Per Employee | 1.3M | |
Working Capital Per Executive | 304.6M |
Complementary Tools for Moderna Stock analysis
When running Moderna's price analysis, check to measure Moderna's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moderna is operating at the current time. Most of Moderna's value examination focuses on studying past and present price action to predict the probability of Moderna's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moderna's price. Additionally, you may evaluate how the addition of Moderna to your portfolios can decrease your overall portfolio volatility.
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |